Shareholders approve equity plan amendment adding 2M shares, reverse stock split authorization, and elect all director nominees
Co-Diagnostics, Inc. shareholders at a November 13, 2026 special meeting approved Amendment No. 1 to the 2025 Equity Incentive Plan, increasing the share reserve by 2,000,000 shares to 2,223,333 total shares authorized. Shareholders also approved a reverse stock split authorization allowing the board to effect a reverse split at a ratio between 1-for-2 and 1-for-750 within twelve months, and approved the potential exercise of 3,404,724 warrants at $1.56 per share issued pursuant to an August 2026 inducement agre...
Key takeaways
Equity plan amendment approved: Share reserve increased by 2,000,000 shares to 2,223,333 total authorized shares under the 2025 Equity Incentive Plan.
Reverse stock split authorized: Shareholders approved an amendment permitting the board to effect one or more reverse splits at ratios from 1-for-2 to 1-for-750 within twelve months without further shareholder approval.
Warrant exercise approved: Shareholders approved potential exercise of 3,404,724 warrants at $1.56 per share issued August 3, 2026 under an inducement agreement, requiring approval under Nasdaq Listing Rule 5635(d).
Convertible notes conversion approved: Shareholders approved issuance of common stock upon conversion of secured convertible notes from the financing transaction.
Directors elected: All five nominees (Dwight Egan, Eugene Durenard, Richard Serbin, James Nelson, Edward Murphy) elected with terms expiring at the next annual meeting.
Auditor ratified: Tanner LLC ratified as independent registered public accounting firm for the year ending December 31, 2026.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow CODX in real time
Get material earnings, filing, IR, and earnings-call alerts by email.